Draft:Treat and extend

Submission declined on 13 December 2023 by S0091 (talk).

The proposed article does not have sufficient content to require an article of its own, but it could be merged into the existing article at Anti-VEGF. Since anyone can edit Wikipedia, you are welcome to add that information yourself. Thank you.

If you would like to continue working on the submission, click on the "Edit" tab at the top of the window.
If you have not resolved the issues listed above, your draft will be declined again and potentially deleted.
If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors.
Please do not remove reviewer comments or this notice until the submission is accepted.

Where to get help

If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews.
If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed.

How to improve a draft

Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia.
Help:Wikitext – how to use the markup
Help:Referencing for beginners – how to include references
Wikipedia:Article development – how to develop your article
Wikipedia:Writing better articles – how to improve your article
Wikipedia:Verifiability – make sure your article includes reliable third-party sources

You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article.

Improving your odds of a speedy review

To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags.

Add tags to your draft

Editor resources

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL
Easy tools: Citation bot (help) | Advanced: Fix bare URLs

Declined by S0091 5 months ago. Last edited by Citation bot 2 months ago. Reviewer: Inform author.

Resubmit

Please note that if the issues are not fixed, the draft will be declined again.

A treat and extend (T&E) protocol of treatment is used for the use of intravitreal anti-VEGF agents that are used for the treatment of specific eye disorders. This treatment protocol is used as alternative to pro re nata (PRN) or as needed. It is typically started with more than three consecutive intravitreal injections every month until disease is relieved, followed by gradual extension of the treatment interval in increments of two to four weeks, up to a maximum interval of twilve to sixteen weeks. When disease activity recurs, treatment intervals will be shortened.^[1]^[2]^[3]^[4]^[5]

References[edit]

^ Skelly, Adrian; Bezlyak, Vladimir; Liew, Gerald; Kap, Elisabeth; Sagkriotis, Alexandros (September 1, 2019). "Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients". Vision. 3 (3): 41. doi:10.3390/vision3030041. PMC 6802800. PMID 31735842.
^ Chaikitmongkol, Voraporn; Sagong, Min; Lai, Timothy Y.Y.; Tan, Gavin S.W.; Ngah, Nor Fariza; Ohji, Masahito; Mitchell, Paul; Yang, Chang-Hao; Ruamviboonsuk, Paisan; Wong, Ian; Sakamoto, Taiji; Rajendran, Anand; Chen, Youxin; Lam, Dennis S.C.; Lai, Chi-Chun; Wong, Tien Yin; Cheung, Chui Ming Gemmy; Chang, Andrew; Koh, Adrian (November 24, 2021). "Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society". Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.). 10 (6): 507–518. doi:10.1097/APO.0000000000000445. PMC 8673847. PMID 34839342.
^ Cheng, Cheng-Kuo; Chen, Shih-Jen; Chen, Jiann-Torng; Chen, Lee-Jen; Chen, San-Ni; Chen, Wen-Lu; Hsu, Sheng-Min; Lai, Chien-Hsiung; Sheu, Shwu-Jiuan; Wu, Pei-Chang; Wu, Wei-Chi; Wu, Wen-Chuan; Yang, Chung-May; Yeung, Ling; Chen, Ta-Ching; Yang, Chang-Hao (January 15, 2022). "Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan". BMC Ophthalmology. 22 (1): 25. doi:10.1186/s12886-021-02231-8. PMC 8760882. PMID 35033037.
^ Ross, Adam H.; Downey, Louise; Devonport, Helen; Gale, Richard P.; Kotagiri, Ajay; Mahmood, Sajjad; Mehta, Hemal; Narendran, Niro; Patel, Praveen J.; Parmar, Nina; Jain, Nitin (October 1, 2020). "Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration". Eye. 34 (10): 1825–1834. doi:10.1038/s41433-019-0747-x. PMC 7608090. PMID 31900438.
^ Chaudhary, Varun (March 1, 2023). "Treat & extend in neovascular age-related macular degeneration: how we got here and where do we go next?". Eye. 37 (4): 581–583. doi:10.1038/s41433-022-02221-0. PMC 9998426. PMID 36064769.

External links[edit]

Treat-and-Extend Strategy: Is There a Consensus?, American Academy of Ophthalmology

[1] Skelly, Adrian; Bezlyak, Vladimir; Liew, Gerald; Kap, Elisabeth; Sagkriotis, Alexandros (September 1, 2019). "Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients". Vision. 3 (3): 41. doi:10.3390/vision3030041. PMC 6802800. PMID 31735842.

[2] Chaikitmongkol, Voraporn; Sagong, Min; Lai, Timothy Y.Y.; Tan, Gavin S.W.; Ngah, Nor Fariza; Ohji, Masahito; Mitchell, Paul; Yang, Chang-Hao; Ruamviboonsuk, Paisan; Wong, Ian; Sakamoto, Taiji; Rajendran, Anand; Chen, Youxin; Lam, Dennis S.C.; Lai, Chi-Chun; Wong, Tien Yin; Cheung, Chui Ming Gemmy; Chang, Andrew; Koh, Adrian (November 24, 2021). "Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society". Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.). 10 (6): 507–518. doi:10.1097/APO.0000000000000445. PMC 8673847. PMID 34839342.

[3] Cheng, Cheng-Kuo; Chen, Shih-Jen; Chen, Jiann-Torng; Chen, Lee-Jen; Chen, San-Ni; Chen, Wen-Lu; Hsu, Sheng-Min; Lai, Chien-Hsiung; Sheu, Shwu-Jiuan; Wu, Pei-Chang; Wu, Wei-Chi; Wu, Wen-Chuan; Yang, Chung-May; Yeung, Ling; Chen, Ta-Ching; Yang, Chang-Hao (January 15, 2022). "Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan". BMC Ophthalmology. 22 (1): 25. doi:10.1186/s12886-021-02231-8. PMC 8760882. PMID 35033037.

[4] Ross, Adam H.; Downey, Louise; Devonport, Helen; Gale, Richard P.; Kotagiri, Ajay; Mahmood, Sajjad; Mehta, Hemal; Narendran, Niro; Patel, Praveen J.; Parmar, Nina; Jain, Nitin (October 1, 2020). "Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration". Eye. 34 (10): 1825–1834. doi:10.1038/s41433-019-0747-x. PMC 7608090. PMID 31900438.

[5] Chaudhary, Varun (March 1, 2023). "Treat & extend in neovascular age-related macular degeneration: how we got here and where do we go next?". Eye. 37 (4): 581–583. doi:10.1038/s41433-022-02221-0. PMC 9998426. PMID 36064769.

[1]

[2]

[3]

[4]

[5]

See also[edit]

References[edit]

External links[edit]